Cargando…

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) need to be approached carefully given the high incidence of pulmonary toxicity. Pemetrexed (PEM) is the key drug for the treatment of NSCLC. However, its safety, especially with respect to the exacerbation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Motoyasu, Shukuya, Takehito, Takahashi, Fumiyuki, Mori, Keita, Suina, Kentaro, Asao, Tetsuhiko, Kanemaru, Ryota, Honma, Yuichiro, Muraki, Keiko, Sugano, Koji, Shibayama, Rina, Koyama, Ryo, Shimada, Naoko, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107964/ https://www.ncbi.nlm.nih.gov/pubmed/25012241 http://dx.doi.org/10.1186/1471-2407-14-508

Ejemplares similares

Cerebral infarction in advanced non-small cell lung cancer: a case control study
por: Kato, Motoyasu, et al.
Publicado: (2016)

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
por: Nakamura, Kota, et al.
Publicado: (2017)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
por: Miyashita, Yosuke, et al.
Publicado: (2020)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
por: Shimamura, Shoko Sonobe, et al.
Publicado: (2022)

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
por: Kurokawa, Kana, et al.
Publicado: (2022)

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
por: Kurokawa, Kana, et al.
Publicado: (2022)

Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
por: Nurwidya, Fariz, et al.
Publicado: (2021)

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines
por: Xu, Shiting, et al.
Publicado: (2023)

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
por: Kato, Motoyasu, et al.
Publicado: (2021)

Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer
por: Sekimoto, Yasuhito, et al.
Publicado: (2016)

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
por: Ko, Ryo, et al.
Publicado: (2021)

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
por: Kanamori, Koichiro, et al.
Publicado: (2023)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Shiting, et al.
Publicado: (2022)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
por: Hayakawa, Daisuke, et al.
Publicado: (2019)

High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
por: Sumiyoshi, Issei, et al.
Publicado: (2021)

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
por: Ando, Katsutoshi, et al.
Publicado: (2014)

SCLC-J1, a novel small cell lung cancer cell line
por: Ohara, Kazuo, et al.
Publicado: (2021)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Hermansky-Pudlak syndrome-associated pneumothorax with rapid progression of respiratory failure: a case report
por: Kato, Yukari, et al.
Publicado: (2020)

Loxoprofen-induced interstitial pneumonia: a case report
por: Kato, Motoyasu, et al.
Publicado: (2016)

LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer
por: Jotatsu, Takanobu, et al.
Publicado: (2016)

Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
por: Murakami, Akiko, et al.
Publicado: (2014)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2012)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323
por: Kozuki, Toshiyuki, et al.
Publicado: (2020)

Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
por: Ueda, Shoko, et al.
Publicado: (2021)

Idiopathic dendriform pulmonary ossification diagnosed by bronchoscopic lung cryobiopsy: A case report
por: Sekimoto, Yasuhito, et al.
Publicado: (2021)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2012)

Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID‐19 infection
por: Tanabe, Yuki, et al.
Publicado: (2022)

Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
por: Shukuya, Takehito, et al.
Publicado: (2023)

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
por: Hasegawa, Nobuhiko, et al.
Publicado: (2021)

Severe mediastinitis over a month after endobronchial ultrasound‐guided transbronchial needle aspiration
por: Kurokawa, Kana, et al.
Publicado: (2019)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer
por: Otsubo, Kohei, et al.
Publicado: (2017)

A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients
por: Sekine, Ikuo, et al.
Publicado: (2020)

Two Lung Masses with Different Responses to Pemetrexed
por: Park, Kwang Young, et al.
Publicado: (2010)

Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
por: Kataoka, Shunichi, et al.
Publicado: (2022)

Regional heterogeneity in response of airway epithelial cells to cigarette smoke
por: Baskoro, Hario, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m82s2lbuvqu1755guunp6gsct1